Company news

Veru Inc. news in 2022

Veru Inc.'s news releases, calls and decks from 2022, newest first.

View company

Veru Reports Fiscal 2022 Fourth Quarter and Full Year Financial Results

December 4, 2022

Veru to Report Fiscal 2022 Fourth Quarter and Full Year Financial Results on December 5, 2022

November 27, 2022

Veru Provides Update on FDA Advisory Committee Meeting Regarding Emergency Use Authorization of Sabizabulin to Treat Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome

November 8, 2022

Veru Announces Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with COVID-19 on Supplemental Oxygen at Infectious Disease Week 2022

October 23, 2022

Veru Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

October 3, 2022

Veru Announces FDA has Updated the Meeting Date for the Advisory Committee Meeting to Review Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome

September 18, 2022

Veru Announces Date for FDA Advisory Committee Meeting to Review Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome

September 6, 2022

Veru Granted Expedited Provisional Registration Regulatory Pathway for Sabizabulin Treatment in Hospitalized COVID-19 Patients by Australia’s Therapeutic Goods Administration

August 21, 2022

Veru Announces Appointment of Jason Davies to Lead EMEA, LATAM and APAC Infectious Disease Franchise for Veru International Focused on Hospitalized COVID-19 Patients

August 18, 2022

Veru Reports Third Quarter Fiscal 2022 Financial Results; Progresses Sabizabulin Treatment for COVID-19 Towards Regulatory Decisions in Key Territories

August 10, 2022

Veru Announces Presentation of Phase 3 Study of Sabizabulin for the Treatment of Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome at the 11th International Conference on Emerging Infectious Diseases (ICEID) on August...

August 8, 2022

Veru to Report Fiscal 2022 Third Quarter Financial Results, Host Conference Call on August 11th

July 27, 2022

Veru Announces New England Journal of Medicine Evidence Publication of Phase 3 Clinical Trial Results Demonstrating that Sabizabulin Treatment Significantly Reduced Deaths in High-Risk Hospitalized COVID-19 Patients

July 5, 2022

Veru Submits Emergency Use Authorization (EUA) Application to U.S. FDA for Sabizabulin, its Novel, Oral Antiviral and Anti-Inflammatory Drug Candidate for Hospitalized COVID-19 Patients at High Risk for ARDS

June 6, 2022

Veru Announces Presentation of Final Positive Phase 1b/2 Clinical Trial Results for Sabizabulin in Metastatic Castration Resistant Prostate Cancer at the 2022 American Society of Clinical Oncology Annual Meeting

June 5, 2022

Veru Announces Appointment of Joel Batten to Lead U.S. Infectious Disease Franchise to Focus on Hospitalized COVID-19 Patients

May 17, 2022

Veru Reports Second Quarter Fiscal 2022 Results and Progress of Sabizabulin for COVID-19 Toward a Request for Emergency Use Authorization

May 11, 2022

FDA Has Granted Veru a Pre-Emergency Use Authorization (EUA) Meeting Date for Positive Sabizabulin Phase 3 COVID-19 Study

May 1, 2022

Veru Announces Oral Late-Breaking Presentation of Phase 2 Data of Sabizabulin for the Treatment of Hospitalized Severe COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome at the 32nd European Congress of Clinical Microbiology & Infe...

April 24, 2022

Veru’s Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring Committee Halts Study Early for Overwhelming Efficacy

April 10, 2022

Veru Announces Acceptance of Two Abstracts for Presentation at the 39th Miami Breast Cancer Conference

March 3, 2022

Veru Announces the Presentation of Updated Data from the Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2022 ASCO Genitourinary Cancers Symposium

February 16, 2022

Veru Reports that Independent Data Monitoring Committee for the Phase 3 Sabizabulin COVID-19 Clinical Study Recommends Continuing Study as Planned

February 13, 2022

Veru Reports First Quarter Fiscal 2022 Results as US FC2 Prescription Net Revenues Climb 27%

February 8, 2022

Veru Enters into Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate Enobosarm in Combination with Verzenio® in Phase 3 ENABLAR-2 Trial

January 31, 2022

Veru Announces FDA Grant of Fast Track Designation for Sabizabulin for the Treatment of Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome

January 30, 2022

Veru to Report Fiscal 2022 First-Quarter Financial Results, Host Conference Call on February 9th

January 25, 2022

Veru Announces FDA Grant of Fast Track Designation for Enobosarm for the Treatment of AR+ ER+ HER2- Metastatic Breast Cancer

January 9, 2022

Calls in 2022

Decks in 2022